CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Completed· 6 enrolled
Drug / intervention
Antitumor Bdrug
Likely dose
Antitumor B 1200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03459729
NCT03459729Early Ph 1Completed
CompareCT.gov

PK Analysis of Antitumor B in Patients With Oral Cancer

Medical College of Wisconsin·interventional·Posted Mar 9, 2018·Updated Jan 16, 2025

In Brief

A Early Phase 1 clinical trial evaluating Antitumor B for Squamous Cell Carcinoma of the Oral Cavity. Completed, enrolled 6 participants across 1 site.

Detailed Summary

A Window of Opportunity Clinical Trial. This study design permits examination of effects of an oral agent on cancer patients during the "window" between diagnosis of their cancer and their definitive cancer surgery. Similar to a phase 0 study, the trial design permits examination of the biologic effects of an agent; in this study pharmacokinetic properties will be examined.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSquamous Cell Carcinoma of the Oral Cavity
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Early Ph 1CompletedFinished
201820192020202120222023202420252026
First PostedMar 9, 2018
Enrollment StartAug 24, 2021
Primary CompletionFeb 15, 2022
Study CompletionFeb 16, 2022
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 8.3 years ago

Interventions

Antitumor Bdrug

Study participants will take the natural botanical compound ATB during a short window (seven to 28 days). It will be administered at a dose of 1200 mg three times per day (roughly spaced every 8 hours).